Afya (NasdaqGS:AFYA) Valuation Check After Mixed Short Term And Three Year Shareholder Returns

Afya (NasdaqGS:AFYA) continues to attract attention after recent share price moves, with investors weighing its medical education focus in Brazil against mixed return patterns over the past year and a longer three year gain.

See our latest analysis for Afya.

At a last close of $14.06, Afya’s recent 90 day share price return of 3% contrasts with a decline of 5.95% year to date, while the 1 year total shareholder return is down 20.03% against a 3 year total shareholder return of 23.23%. This suggests that longer term holders have fared better than more recent entrants.

If Afya’s recent moves have you thinking about where else to put fresh capital to work, it could be a good moment to broaden your search with 20 top founder-led companies

With Afya trading at $14.06 and an indicated discount to both analyst targets and intrinsic estimates, the key question is whether the stock still sits below fair value or whether the market is already pricing in future growth.

Most Popular Narrative: 5.4% Undervalued

According to the most followed narrative, Afya’s fair value of $14.86 sits slightly above the last close at $14.06, which points to only a modest discount and places more emphasis on the quality and durability of future earnings rather than on a large valuation gap.

Afya’s growth prospects are linked to demand for healthcare professionals, regulatory dynamics in medical education, and opportunities in digital transformation. However, risks such as economic volatility, regulatory changes, and increasing competition could affect its performance.

Read the complete narrative.

Curious what sits behind that fair value call. The narrative highlights specific revenue, earnings, and margin assumptions that differ from recent share price trends.

Result: Fair Value of $14.86 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this fair value story could be shaken if Brazil’s economy weakens further or if tighter regulation slows new medical seat approvals and acquisition plans.

Find out about the key risks to this Afya narrative.

Next Steps

Mixed signals on Afya so far. If you want to act while sentiment is still split, review the key risks and potential upsides in 5 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Afya has sharpened your focus on opportunities, do not stop here. Fresh ideas can help you stay one step ahead of the market.

• Target potential bargains by scanning 46 high quality undervalued stocks that combine quality fundamentals with prices that may sit below their implied worth.
• Build a portfolio with staying power by reviewing 65 resilient stocks with low risk scores that carry lower overall risk scores.
• Hunt for future standouts by checking the screener containing 22 high quality undiscovered gems before they appear on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com